nach oben

Drugs

Erschienen in:

01.07.2008 | Leading Article

Eculizumab in Paroxysmal Nocturnal Haemoglobinuria

verfasst von: Dr Lisa Charneski, Priti N. Patel

Erschienen in: Drugs | Ausgabe 10/2008

Einloggen, um Zugang zu erhalten

Abstract

Eculizumab is a monoclonal antibody that binds with high affinity to the complement protein C5, preventing terminal complement-mediated intravascular haemolysis in patients with paroxysmal nocturnal haemoglobinuria (PNH). In three well designed clinical trials in patients with PNH, eculizumab blocked serum haemolytic activity and decreased transfusion rates. Pooled data from the three clinical trials demonstrated that eculizumab treatment decreased the overall thromboembolism rate in patients with PNH. Eculizumab carries a black box warning for the potential increased risk of meningococcal infections and requires patients to receive the meningococcal vaccine at least 2 weeks before starting treatment. Eculizumab is the first drug to be approved by the US FDA for the treatment of PNH and is a novel treatment that offers a new option for patients with PNH.

The use of trade names is for product identification purposes only and does not imply endorsement.

Strubing P. Paroxysmale haemoglobinurie. Deutsche Med Wochenschrift 1882; 8: 1–16CrossRef

Nishimura J, Murakami Y, Kinoshita T. Paroxysmal noctrnal hemoglobinuria: an acquired genetic disease. Am J Hematol 1999; 62: 175–82PubMedCrossRef

Brodsky RA. New insights into paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program 2006; 24-8: 516

Meletis J, Terpos E. Recent insights into pathophysiology of paroxysmal nocturnal hemoglobinuria. Med Sci Monit 2003; 9: 161–72

Parker CJ. The pathophysiology of paroxysmal nocturnal hemoglobinuria. Exp Hematol 2007; 35: 523–33PubMedCrossRef

Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2007; 137: 181–92PubMedCrossRef

Parham Peter, editor. The immune system. New York: Garland Publishing/Elsevier science Ltd., 2000: 185

Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253–8PubMedCrossRef

Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106: 3699–709PubMedCrossRef

10.

FDA News. FDA approves first-of-its-kind drug to treat rare blood disorder [online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01589.html [Accessed 2007 Nov 1]

11.

Soliris (eculizumab) prescribing information. Cheshire (CT): Alexion Pharmaceuticals, Inc.

12.

Matis LA, Rollins SA. Complement-specific antibodies: designing novel anti-inflammatories. Nat Med 1995; 1: 839–42PubMedCrossRef

13.

Hillmen P, Hall C, Marsh J, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350: 552–9PubMedCrossRef

14.

Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005; 106: 2559–65PubMedCrossRef

15.

Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233–43PubMedCrossRef

16.

Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008; 111: 1840–7PubMedCrossRef

17.

Hillmen R, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110: 4123–8PubMedCrossRef

Titel: Eculizumab in Paroxysmal Nocturnal Haemoglobinuria
verfasst von: Dr Lisa Charneski
Priti N. Patel
Publikationsdatum: 01.07.2008
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 10/2008
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200868100-00001

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2008

Drugs in Development for Hepatitis C

Tipranavir

Eszopiclone

Evidence-Based Therapy for Cutaneous Sarcoidosis

Irbesartan/Hydrochlorothiazide

Calcineurin Inhibitor Sparing in Paediatric Solid Organ Transplantation